Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study - Sehgal, A; Hoda, D; Riedell, PA (Lancet Oncol, 2022)